more

T2 Biosystems (TTOO)

(Delayed Data from NSDQ)

$3.70 USD

+0.51 (15.83%)

Updated May 10, 2024 04:00 PM ET

After-Market: $3.68 -0.02 (-0.41%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.20%
2	Buy	18.04%
3	Hold	9.52%
4	Sell	5.20%
5	Strong Sell	2.60%
S&P	500	11.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

Top 38% (95 out of 250)

Industry: Medical - Instruments

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Company News for May 26, 2020

by Zacks Equity Research Published on May 26,2020

Companies In The News Are: TTWO, XERS, SPLK, NAVB

medical

Is the Options Market Predicting a Spike in T2 Biosystems (TTOO) Stock?

by Zacks Equity Research Published on May 26,2020

Investors need to pay close attention to T2 Biosystems (TTOO) stock based on the movements in the options market lately.

TTOOPositive Net Change

medical

T2 Biosystems (TTOO) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research Published on April 30,2020

T2 Biosystems' (TTOO) first-quarter performance is likely to reflect growth in product revenues.

Is the Options Market Predicting a Spike in T2 Biosystems (TTOO) Stock?

by Zacks Equity Research Published on March 26,2020

Investors need to pay close attention to T2 Biosystems (TTOO) stock based on the movements in the options market lately.

TTOOPositive Net Change

Analysts Estimate T2 Biosystems (TTOO) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research Published on November 05,2019

T2 Biosystems (TTOO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

TTOOPositive Net Change

Earnings Preview: T2 Biosystems (TTOO) Q3 Earnings Expected to Decline

by Zacks Equity Research Published on October 31,2019

T2 Biosystems (TTOO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

TTOOPositive Net Change

Are Options Traders Betting on a Big Move in T2 Biosystems (TTOO) Stock?

by Zacks Equity Research Published on August 28,2019

Investors need to pay close attention to T2 Biosystems (TTOO) stock based on the movements in the options market lately.

TTOOPositive Net Change

medical

T2 Biosystems (TTOO) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research Published on July 30,2019

T2 Biosystems (TTOO) delivered earnings and revenue surprises of -9.38% and -10.07%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

TTOOPositive Net Change

T2 Biosystems (TTOO) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research Published on May 02,2019

T2 Biosystems (TTOO) delivered earnings and revenue surprises of -13.33% and 31.83%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

TTOOPositive Net Change

Can Mass Cytometry Drive Fluidigm's (FLDM) Q1 Earnings?

by Zacks Equity Research Published on April 29,2019

Better-than-expected performance at mass cytometry market and higher revenues is likely to aid Fluidigm's (FLDM) in Q1 earnings. However, sluggishness in microfluidics market remains a dampener.

Integer Holdings (ITGR) Q1 Earnings: What's in the Cards?

by Zacks Equity Research Published on April 29,2019

Better-than-expected performance at C&V and Cardiac & Neuromodulation product lines and higher revenues might aid Integer Holdings (ITGR) in Q1. But decline in non-medical sales might be a dampener.

T2 Biosystems (TTOO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research Published on April 25,2019

T2 Biosystems (TTOO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.